Corporate ActionApr 26, 2026, 05:34 AM
HCWB to raise up to $5.6M in public offering; faces Nasdaq delisting
AI Summary
HCW Biologics Inc. is launching a public offering to raise up to $5.6 million by selling common stock or pre-funded warrants. The offering is priced at an assumed $0.411 per share, with directors and existing investors committing to purchase $600,000. Proceeds will fund preclinical and clinical development, including the HCW9302 clinical trials, and general corporate purposes. The company is also facing potential delisting from Nasdaq due to non-compliance with the minimum bid price requirement and has a hearing scheduled for May 5, 2026.
Key Highlights
- Public offering to raise up to $5.6 million.
- Offering up to 13,625,304 shares or pre-funded warrants.
- Assumed public offering price of $0.411 per share.
- Directors and executive officers to purchase $430,000 of securities.
- Existing investors to purchase $170,000 of securities.
- Placement agent fee of 4.0% of gross proceeds.
- Nasdaq hearing scheduled for May 5, 2026, regarding minimum bid price non-compliance.
- First patient dosed for HCW9302 clinical trial on November 17, 2025.